Focal Cryoablation Highlighted in Urology Times Best of AUA Or...(hus far reported similar outcomes to ear...),Health

"Physicians and patients have struggled to find a middle ground between under-treating prostate cancer, by 'watchful waiting,' and over-treating through radical prostatectomy," said Endocare Chairman, CEO and President Craig T. Davenport. "There is a growing body of evidence that focal cryoablation may be an effective option for men who want to consider destroying localized focal cancer while at the same time preserving their quality of life."

Also at the conference this year, the AUA for the first time ever adopted an official set of clinical guidelines, or "best practices," for prostate cryoablation. These new guidelines, which included focal cryoablation, are further evidence of the growing acceptance of cryoablation within the urology physician community, Davenport noted.

About Endocare

Endocare, Inc. -- http://www.endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

Statements contained in this release that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in "Risk Factors" in the Company's Forms 10-K, Forms 10-Q, and other filings with the Securities and Exchange Commission. Suc
'/>"/>